Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies

Inclusion Criteria:

- Subject is ≥ 18 years at the time of signing informed consent;

- Confirmed malignant hematologic disease or lymphoid malignancy that has relapsed or is
refractory to standard therapy and has exhausted all available therapies;

- Presence of measurable or evaluable disease;

- Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2;

- Contraceptives or other approved avoidance of pregnancy measures

Exclusion Criteria:

- Allogenic stem cell transplant recipient presenting with graft versus host disease
(GVHD) either active or requiring immunosuppression;

- Concomitantly taking anti-cancer therapy (bisphosphonates are permitted);

- Undergone major surgery ≤ 2 weeks prior to starting study drug;

- Evidence of mucosal or internal bleeding;

- Impaired cardiac function or conduction defect;

- Concurrent severe and/or uncontrolled medical conditions